Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Coronary Artery Disease|December 9, 2008
Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunctionSabine Westphal, Claudia Abletshauser, Claus Luley
Angiology|April 17, 2008
Fluvastatin treatment and withdrawal: effects on endothelial functionSabine Westphal, Claudia Abletshauser, Claus Luley
International Journal of Cardiology|August 8, 2006
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trialsHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
Renal Failure|August 25, 2006
The renal safety profile of fluvastatin: results of a pooled analysisHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
Microcirculation (New York, N.Y. : 1994)|October 2, 2007
Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery diseaseTakahiro Higuchi, Claudia Abletshauser, Stephan G Nekolla, et al.
Cardiology|May 13, 2006
Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administrationHubert Scharnagl, Monika Vogel, Claudia Abletshauser, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2004
Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetesKarl Winkler, Claudia Abletshauser, Isolde Friedrich, et al.
The Journal of Clinical Endocrinology and Metabolism|December 6, 2002
Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of actionKarl Winkler, Claudia Abletshauser, Michael M Hoffmann, et al.
Expert Opinion on Pharmacotherapy|October 19, 2010
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAINSebastian M Schellong, Sylvia Haas, Andreas Greinacher, et al.
American Heart Journal|February 15, 2011
Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY studyUlrich Tebbe, Sebastian M Schellong, Sylvia Haas, et al.
Pageof 2